hims eli lilly - Search News

News

Lilly soars

Eli Lilly stock spikes as efficacy of new weight-loss pill rivals Ozempic

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of obesity and diabetes.

Seeking Alpha on MSN · 16d

Eli Lilly weight loss therapy added to Hims & Hers platform (update)

Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of branded versions of Eli Lilly’s (NYSE:LLY) popular weight loss therapy tirzepatide for sale on its platform.

The Detroit News · 16h

Lilly soars after weight-loss pill results rival Ozempic’s

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

19hon MSN

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Modern Healthcare15d

Eli Lilly denies affiliation with Hims & Hers

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

HIMS Stock: Time For A Turnaround?

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

18h

Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Pharmaceutical Technology1d

The GLP-1 drug shortage is over. What’s next for the compounders?

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results